Fig. 5: A representative case demonstrating the capability of 68Ga-grazytracer PET in determining pseudoprogression. a–e, A patient with right lung adenocarcinoma. | Nature Communications

Fig. 5: A representative case demonstrating the capability of 68Ga-grazytracer PET in determining pseudoprogression. a–e, A patient with right lung adenocarcinoma.

From: 68Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1/2 clinical trial

Fig. 5

a The baseline 18F-FDG PET/CT revealed a mass (5.2 × 3.3 cm in size) with intense 18F-FDG uptake (SUVmax of 7.6) in the upper lobe of the right lung. b 18F-FDG PET/CT after two cycles of treatment (immunotherapy and chemotherapy) showed no changes in tumor size, while the 18F-FDG uptake was increased compared with baseline (SUVmax of 11.3 vs. 7.6). c 68Ga-grazytracer PET/CT after two cycles of treatment showed a mass in the upper lobe of the right lung with inhomogeneous increased activity (arrows; SUVmax of 5.2). d Chest CT after 3 days of 68Ga-grazytracer PET/CT revealed no change in the tumor size. e Chest CT after 19 days of 68Ga-grazytracer PET/CT indicated a significant reduction in tumor size. Arrows indicate tumors in the PET, PET/CT, and CT images.

Back to article page